T-Cypher Bio Ltd
- Biotech or pharma, therapeutic R&D
T-Cypher address the lack of tumour-specific targets across a range of solid tumours using our proprietary target discovery platform, T-Cα. The platform maps and validates druggable, high copy number, HLA-presented targets, including targets derived from the ‘dark genome’. Our pipeline of T cell engagers against novel targets is addressing a range of solid tumour indications and each program has the potential to impact tens of thousands of patients with metastatic disease every year.
We will initiate clinical studies by the end of '26 on our lead solid tumour programme, swiftly followed by a second programme in a complementary set of indications. HQ in Oxford, UK.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}